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Helicobacter species have been found in human bile and biliary tract (BT) tissue and are suspected to cause BT diseases, including
gallbladder and extrahepatic cancers, collectively referred to in this work as BT cancers. We conducted a literature review of the
epidemiological evidence linking the presence of Helicobacter species in bile or BT biopsies to BT cancers and benign diseases. Reports
showed great variability with respect to study methods. Nine studies of BT cancers were identified, all with 30 or fewer BT cancers;
eight included cancer-free control subjects and used polymerase chain reaction (PCR) as a means of Helicobacter species detection. In
four of these studies, Helicobacter species were detected in patients with BT cancer significantly more frequently than in controls, at
least when controls without BT diseases were used. In two studies, no Helicobacter species were detected in either cases or controls.
Helicobacter species were also often detected in benign BT diseases such as gallstone disease or chronic cholecystitis. As our current
knowledge relies on a few small studies that showed substantial differences, larger studies and more standardised protocols for
detecting DNA and antibodies against Helicobacter species are needed to investigate a potential association with BT cancer.
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Gallbladder cancers (ICD-10 code C23) and extrahepatic biliary
tract cancers (code C24, hereafter referred to collectively as biliary
tract (BT) cancers) are relatively rare malignancies with wide
variations in incidence rates worldwide (Figure 1). The highest BT
cancer incidence rates are seen within Latin America (e.g., up to
9.3 per 100000 for men and 25.3 per 100000 for women in Chile),
but the disease is also frequent in Northern India, Japan, Korea,
and some Eastern European countries (Curado et al, 2007).
Although gallbladder cancer is the most common BT cancer, its
overall incidence, and its proportion of all BT cancer, varies
substantially across regions and genders (e.g., 18.9% among men
in Denmark and 93.6% among women in New Delhi, India,
Figure 1) (Saika and Matsuda, 2007). It usually occurs in patients
with a history of gallstone disease and chronic cholecystitis (Randi
et al, 2006).
Helicobacter pylori (H. pylori) infection is a well-established
cause of stomach cancer (Amieva and El-Omar, 2008). Since the
discovery of H. pylori in 1982, 30 other Helicobacter species have
been isolated from the stomach, intestinal tract, and liver of
mammals and birds. A few species found in human bile and BT
tissue biopsies (Helicobacter bilis (H. bilis), Helicobacter pullorum
(H. pullorum), Helicobacter hepaticus (H. hepaticus), and H. pylori)
have been suspected to cause BT diseases. We aimed to review
current information on Helicobacter species in BT cancer and
benign BT diseases in humans and to help delineate future
research needs on the topic.
MATERIALS AND METHODS
We carried out several detailed searches of the database MEDLINE
through PUBMED, using the following entry terms in the first
search round: (‘Gallbladder Neoplasms’[Mesh] OR ‘Gallbladder’
[Mesh] OR ‘Gallbladder Diseases’[Mesh] OR Gallbladder [Text
Word]) AND (‘Helicobacter’[Mesh] OR ‘Helicobacter Infections’
[Mesh] OR ‘Helicobacter hepaticus’[Mesh] OR ‘Helicobacter
pylori’[Mesh] OR ‘Helicobacter’[Text Word]). We then repeated
the search using ‘Biliary tract neoplasms’, ‘Cholangiocarcinoma’,
‘Cholelithiasis’, ‘Cholecystis’, and ‘Gallstone’ as entry terms instead
of ‘Gallbladder neoplasms’. Other MEDLINE searches were
subsequently carried out using ‘Helicobacter bilis’ and ‘Helico-
bacter pullorum’ as single entry terms. Regional databases for
India, Southeast Asia, and Latin America (the Index Medicus for
South-East Asia Region (IMSEAR), Latin American and Caribbean
Centre on Health Sciences Information (LILACS) and Indian
Medlars Center National Informatics Centre (INDMED) databases,
respectively) were also searched. Finally, we reviewed the reference
lists of all identified relevant studies. No restrictions on date or
publication language were applied. After exclusion of case-series
with fewer than five patients or biological specimens, we retained
all relevant human studies on BT cancer and their possible or
proven precursor lesions published up to January 2008.
For the sake of accuracy and comparability, only the following
methods of direct Helicobacter species detection in bile, gallstones,
or tissue biopsies were considered for the review: (1) amplification
by polymerase chain reaction (PCR), (2) histology (histopathology,
immunohistopathology), and (3) culture. For each of the studies
selected in this review, the following was retrieved whenever
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diagnosis, age and gender of BT cancer cases, type of biological
specimen, method of Helicobacter species detection, type of
Helicobacter species identified, and selection criteria of control
subjects, if present.
RESULTS
Helicobacter species and BT cancers
Nine studies (Table 1) that investigated the presence of
Helicobacter species in the bile or BT tissue biopsies of patients
with BT cancers were identified (Roe et al, 1999; Fukuda et al,
2002; Matsukura et al, 2002; Bulajic et al, 2002a; Fallone et al, 2003;
Murata et al, 2004; Pradhan and Dali, 2004; Kobayashi et al, 2005;
Bohr et al, 2007). Eight studies used PCR as one of the means of
Helicobacter species detection. The PCR primers varied across
studies, but most used genus-specific primers (such as C97-C98) as
a first-line test before undertaking PCR assays that targeted
different Helicobacter species.
Variability among PCR study findings was substantial (between 0
and 82.8% of specimens tested positive for Helicobacter species) even
when analysis was restricted to the same type of biological specimen
(bile or tissue biopsies). Using species-specific primers, H. bilis was
found in 35 out of 67 specimens (52.2%) from four different studies,
whereas H. hepaticus was searched for in two studies, but only found
in 4 out of 19 specimens (21.1%) in one study.
Two studies used histopathology staining to search for
Helicobacter species in BT tissue biopsies. Although Helicobacter-
like bacteria were detected in six out of seven BT cancers from a
study in Nepal, no infections were detected in a German series of
20 BT cancers, using three different methods of staining and
histoimmunochemistry. The German study also reported negative
findings according to several PCR amplification methods, as well
as culture, of fresh gallbladder tissue biopsies. Only one other
study reported an attempt to cultivate these bacteria, but although
tissue biopsies yielded positive PCR results, culture in microaer-
ophilic conditions was unsuccessful (Table 1).
Eight studies had one or more control groups allowing some
comparison with cancer cases (Table 2). Controls were subjects
who underwent the same procedure as cases, and were diagnosed
with benign BT diseases. In three studies, a group of controls
without BT diseases was also included. The presence of
Helicobacter species in bile or BT tissue biopsies was detected
significantly more often in cases than in controls in four studies,
at least when controls without BT diseases were used, but none
were detected in cases in two other studies (Table 2).
Helicobacter species and benign BT diseases
Our literature search identified 20 studies investigating the
presence of Helicobacter species in the bile, gallstones, or BT
tissue biopsies of patients with benign BT diseases (Arnaout et al,
1990; Figura et al, 1998; Fox et al, 1998; Monti et al, 1999;
Rudi et al, 1999; Myung et al, 2000; Harada et al, 2001; Mendez-
Sanchez et al, 2001; Monstein et al, 2002; Roosendaal et al, 2002;
Bulajic et al, 2002b; Chen et al, 2003, 2007; Silva et al, 2003;
Farshad et al, 2004; Abayli et al, 2005; Apostolov et al, 2005;
Neri et al, 2005; Tiwari et al, 2006; Misra et al, 2007). Of these, 19
used PCR amplification methods (Table 3). The choice of
primers varied across studies; some primers were based on genes
coding for the 26kDa H. pylori protein, UreA or UreB enzymes,
whereas others targeted 16S ribosomal RNA fragments,
either common to all organisms of the Helicobacter genus, or
specific to a particular species. Only in two studies, from Chile and
Brazil, did the authors undertake sequencing to identify the
detected species.
Helicobacter species were assessed by PCR in gallstones in five
studies. The frequency of detection varied from 0 to 72%, and the
species identified was believed to be H. pylori in all cases. In one
study from Sweden, H. pylori was searched for and detected in the
nucleus rather than in the envelope of the stones, suggesting an
early presence of the bacteria in the process of gallstone formation
(Monstein et al, 2002). Of 16 PCR studies on Helicobacter species
in bile or BT tissue biopsies in benign BT diseases, the percentage
of positive specimens varied from near 0% in five studies to close
to 50% in six others, with three studies showing intermediate
percentages. Two other studies reported a high prevalence: 29 out
of 30 bile specimens of patients with hepatobiliary diseases were
Helicobacter genus-positive in one study, as were 16 out of 22
gallbladder tissue biopsies of chronic cholecystitis patients in
another.
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Figure 1 Age standardised incidences rates per 100000 (world standard population) for biliary tract cancer, including gallbladder and extrahepatic biliary
tract cancers (ICD-10, C23-C24) in selected areas of the world (1998–2002). *Percentage of gallbladder cancers (code C23 only) on all biliary tract cancers
in women (F) and men (M). Source: Curado et al, 2007.
Helicobacter species in biliary tract cancer
C de Martel et al
195
British Journal of Cancer (2009) 100(1), 194–199 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yHistological and/or immunohistological examination of tissue
biopsies was undertaken in seven studies (including two histological
series of metaplastic gallbladder sections) using various staining
methods and antibodies. Helicobacter-like bacteria were seen in all
but one study, and the percentage of positive specimens varied from
1 to 45%. In three studies, immunohistological staining using anti-
H. pylori antibodies confirmed the histological findings. Attempts to
culture the bacteria were reported in four studies, with three failing
to grow any Helicobacter species from frozen specimens, despite
some success with PCR or histology. In another study, however, 6
out of 77 (8%) fresh gallbladder tissue biopsies from patients with
gallstones grew Helicobacter-like bacteria (Table 3).
Table 2 Helicobacter (H) species detection in biliary tract (BT) cancer patients compared with controls
Reference H-positive/total cases Control diagnosis H-positive/total controls
Roe et al (1999) 6/15 Benign BT diseases 3/11
Matsukura et al (2002)
Japan 13/15 Benign BT diseases 8/16
a
Thailand 11/14 Benign BT diseases 10/26
a
Bulajic et al (2002a)
b 12/15 No BT diseases 3/11
a
Benign BT diseases 37/63
Fukuda et al (2002)
c 10/19 Benign BT diseases 3/19
a
Fallone et al (2003) 0/9 Benign BT diseases 0/75
Murata et al (2004) 4/14 Benign BT diseases 2/16
Kobayashi et al (2005) 5/6 No BT diseases 2/21
a
Benign BT diseases 16/30
Bohr et al (2007) 0/20 No BT diseases 0/22
Benign BT diseases 1/57
d
aFisher’s exact test, Po0.05.
bBulajic et al (2002a) also reported age- and sex-adjusted odds ratio (9.9; 95% confidence interval: 1.4–70.5).
cFive of the cases in this study were
intrahepatic bile duct cancers.
dIn the only positive control specimen, the organism was identified as Helicobacter ganmani.
Table 1 Human studies on Helicobacter (H) species and gallbladder cancers (GC) or extra-hepatic biliary tract cancers (EBC) by testing method
Reference Country
Cancer
diagnosis
Biological
specimen Method Organism
H-positive/
total cases
PCR Primer
Roe et al (1999) Korea EBC Bile 16S (H276f; H676r) H genus 6/15
UreA (HPU1; HPU2) UreA-positive H 7/15
Bulajic et al (2002a) Serbia GC+EBC Bile 16S (various), UreA H genus 12/15
Fukuda et al (2002)
a Japan GC+EBC Bile, tissue biopsies 16S (C97–98) H genus 10/19
16S (species specific) H bilis 6/19
16S (species specific) H hepaticus 4/19
UreA (HPU1; HPU2) UreA-positive H 1/19
Matsukura et al (2002) Japan EBC Bile 16S (species specific) H bilis 13/15
Thailand GC+EBC Bile 16S (species specific) H bilis 11/14
Fallone et al (2003) Canada EBC Bile 16S (C97–98) H genus 0/9
Murata et al (2004) Japan GC+EBC Tissue biopsies 16S (species specific) H bilis 4/14
Kobayashi et al (2005) Japan GC+EBC Bile 16S (C97–98 or C05) H genus 5/6
16S (species specific) H bilis 1/5
16S (species specific) H hepaticus 0/5
UreA UreA-positive H 2/6
Bohr et al (2007) Germany GC Tissue biopsies 16S (C97–20; H3A-20) H genus 0/20
Histology Stain, antibodies, etc.
Pradhan and Dali (2004) Nepal GC+ EBC Tissue biopsies Histopathology,
Warthin-Starry
H genus 6/7
Bohr et al (2007) Germany GC Tissue biopsies Histopathology, Various
staining
H genus 0/20
Histoimmunochemistry H genus 0/20
Culture Conditions
Roe et al (1999) Korea EBC Bile Fresh specimens, under
microaerophilic and
anaerobic conditions
H genus 0/15
Bohr et al (2007) Germany GC Tissue biopsies Fresh specimens, under
microaerophilic conditions
H genus 0/5
aFive cases in this study were intra-hepatic bile duct cancers.
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We aimed to evaluate available evidence linking Helicobacter
infection with BT cancer. It became clear that our current knowl-
edge relies mainly on a few small studies that show substantial
differences in methods and results. In four studies, mainly from
Japan, the detection of Helicobacter species was significantly more
frequent in bile or BT tissue biopsies of cancer patients compared
with controls, at least when controls without BT diseases were
used. Using species-specific primers, the Helicobacter species most
Table 3 Helicobacter (H) species in patients with benign biliary tract diseases
Reference Country
Biological
specimen Method Organism
H-positive/
total cases
PCR Primer
Figura et al (1998) Italy Bile CagA (final product 298bp) CagA-positive H 1/30
Fox et al (1998) Chile Bile, tissue biopsies 16S (C97–98 or C97–05) H genus 22/46
Sequencing H bilis
a 7/8
Sequencing H pullorum 1/8
Monti et al (1999) Argentina Bile Not specified (final product 296bp) H genus 2/26
Rudi et al (1999) Germany Bile 16S (various species specific) H genus 0/73
Myung et al (2000) Korea Bile, tissue biopsies UreA (final product 258bp) H genus 5/53
26kDa H genus 4/53
Stone UreA or 26kDa H genus 7/53
UreA or 26kDa H genus 0/7
Harada et al (2001) Japan Bile, tissue biopsies 16S (C97–98) H genus 2/53
UreA (final product 258bp) UreA-positive H 1/53
Mendez-Sanchez et al
(2001)
Mexico Tissue biopsies 16S (C97–98) H genus 1/95
Bulajic et al (2002b) Serbia Bile UreA (final product 258bp) H genus 35/65
Monstein et al (2002) Sweden Stone 16S (species specific) H pylori 11/20
Roosendaal et al (2002) Netherlands Bile 16S (various specific primers) H pylori 1/21
Chen et al (2003) New Zealand Tissue biopsies 16S (C97–98) H genus 46/85
26kDa H genus 31/46
16S (species specific) H pylori 22/25
16S (C62-C12) H bilis 0/85
Silva et al (2003) Brazil Bile, tissue biopsies 16S (C97–98) H genus 18/46
Sequencing H pylori 18/18
Farshad et al (2004) Iran Stone 16S (species specific) H pylori 6/33
Bile 16S (species specific) H pylori 4/33
Abayli et al (2005) Turkey Stone 16S (final product 349bp) H genus 7/77
Apostolov et al (2005) Ukraine Tissue biopsies 16S (C97–98) H genus 16/22
Neri et al (2005) Italy Bile, tissue biopsies 16S (C95–98) H genus 17/33
Tiwari et al (2006) India Bile 16S H genus 29/30
16S (species specific) H pylori 10/29
UreA (final product 411bp) UreA-positive H 10/29
CagA CagA-positive H 9/29
Chen et al (2007) China Tissue biopsies UreA (final product 411bp) UreA-positive H 15/81
UreB (final product 132bp) UreB-positive H 18/81
UreA or UreB Ure-positive H 22/81
Misra et al (2007) India Stone 16S (species specific) H pylori 8/11
Histology Stain, antibodies, etc.
Arnaout et al (1990) UK Tissue biopsies Histopathology, H&E (PAS), Warthin-Starry H pylori 0/16
b
Fox et al (1998) Chile Tissue biopsies Histopathology, Warthin-Starry H genus 2/18
Mendez-Sanchez et al
(2001)
Mexico Tissue biopsies Histopathology, H&E, Giemsa H genus 0/95
Immuno-histopathology, polyclonal anti H pylori H pylori 1/95
Abayli et al (2005) Turkey Tissue biopsies Histopathology, H&E, gram, Warthin-Starry H genus 18/77
Apostolov et al (2005) Ukraine Tissue biopsies Immuno-histopathology, anti-CagA, anti-VacA,
anti-H pylori
H pylori 13/16
c
Chen et al (2007) China Tissue biopsies Histopathology, Warthin-Starry H genus 71/524
Immuno-histopathology, polyclonal anti-H pylori H pylori 37/71
d
Misra et al (2007) India Tissue biopsies Histopathology, H&E (PAS), Loeffler, Warthin
Starry
H genus 50/111
b
Immuno-histopathology, polyclonal anti-H pylori H pylori 50/111
b
Culture Conditions
Fox et al (1998) Chile Bile, tissue biopsies Frozen specimens, microaerophilic conditions H genus 0/46
Harada et al (2001) Japan Bile Frozen specimens, microaerophilic conditions H genus 0/39
Silva et al (2003) Brazil Bile, tissue biopsies Frozen specimens, microaerophilic conditions H genus 0/46
Abayli et al (2005) Turkey Tissue biopsies Fresh specimens, microaerophilic conditions Oxydase- and
ure-positive
H genus
6/77
aH species identified in this study as H rappini was later reclassified as belonging to the H bilis species (Hanninen et al, 2005).
bOnly specimens with gastric metaplasia were
investigated.
cOnly specimens H genus-positive by PCR were investigated.
dOnly specimens H genus-positive by histology were investigated.
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biopsies of cancer patients was H. bilis. In two studies from Canada
and Germany, however, no Helicobacter species were detected in
BT cancers, despite the use in the German study of numerous
detection techniques.
The presence of Helicobacter species, including H. pylori, was
also often detected in benign BT diseases such as gallstone disease
or chronic cholecystitis, which are recognised risk factors for the
development of BT cancer. However, as with BT cancer, studies of
benign BT diseases showed extreme variability in methods and
findings.
Lower Helicobacter species prevalence was typically observed in
western countries with low BT cancer incidence, and higher
prevalence in countries with high BT cancer incidence, the best
example being Japan. Whether regional variations in the prevalence of
Helicobacter species in BT cancers are real or are a result of differences
in the type and quality of detection methods used is unknown.
Most findings presented here derive from PCR-based studies,
the comparability of which depends on the quality of the biological
specimens (bile, stone, or tissue biopsies; fresh, fixed, or frozen),
the strategy chosen for Helicobacter detection, and potential
problems such as contamination and the presence of Taq poly-
merase inhibitors. The sensitivity and specificity of PCR are also
directly dependent on the choice of primers. In early studies,
primers targeting the genes encoding the 26kDa protein or the
UreA or UreB proteins were often used. Although authors believed
that H. pylori was identified, these findings may also be consistent
with other Helicobacter species. For example, it has been shown
that a gene coding for the 26kDa protein is present in at least eight
other Helicobacter species (including H. bilis and H. pullorum)
with high similarity to the gene in H. pylori (Lundstrom et al,
2001). Similarly, urease structural genes from H. hepaticus are
highly homologous to UreA and UreB from H. pylori (Shen et al,
1998). Even PCR based on the conserved 16S rRNA genes may
yield different results depending on the set of primers used
(Moyaert et al, 2008).
It should be noted that the available sequence information from
non-H. pylori species is still limited. Moreover, for H. pylori, it has
been shown that the intraspecies sequence variability is
substantial, which may hamper uniform detection by a single set
of PCR primers (Kraft et al, 2006). Therefore, it is difficult to
determine whether PCR primers can distinguish Helicobacter
species, especially in patients from different geographic regions.
The sensitivity of PCR is also inversely proportional to the length
of the amplicon. This is particularly important in clinical materials
with a high risk of DNA damage, such as formalin-fixed, paraffin-
embedded tissue biopsies.
Taken together, for reliable Helicobacter species detection and
distinction, it would be advisable, although seldom done so far, to
use multiple PCR primer sets at somewhat reduced annealing
temperatures to permit amplification of imperfectly matching
sequences. Ultimately, amplicons obtained by such PCR should be
sequenced to confirm the true identity of the Helicobacter species.
Means of detection other than PCR also have substantial
drawbacks. Helicobacter species culture has been unsuccessful in
the majority of studies of BT cancer or benign BT diseases. The use
of frozen specimens, which are notoriously difficult to culture, may
explain some of the negative findings (Solnick and Schauer, 2001).
Histology has been considered the gold standard for the detection
of H. pylori in the stomach for many years; however, few studies
have assessed histological changes associated with Helicobacter
infection in the gallbladder or BT tissue. In two studies from India
and China, colonisation by Helicobacter was shown in the
gallbladder epithelium, especially in the areas of gastric metaplasia
(Chen et al, 2007; Misra et al, 2007), but it is not known whether
this was merely a consequence of tissue damage. Serological
studies have not been reviewed here, but cross-reactivity between
the immune response to antigens from H. pylori and H. bilis has
been reported (Ananieva et al, 2002; Pisani et al, 2008).
Furthermore, it has been shown that the prevalence of serological
and histological markers of H. pylori decreases in gastric cancer
(Camorlinga-Ponce et al, 2008) and it is not known whether the
same happens in BT cancer.
An implication of Helicobacter infection in BT cancer pathogen-
esis is nevertheless plausible. Helicobacter species that can survive in,
or colonise, the bile ducts may induce the formation of gallstones
both directly, through the urease activity of some of the species, or
indirectly through a T-cell-dependent immune response (Belzer et al,
2006; Maurer et al, 2007). The colonisation of the mucosa by bacteria
may also aggravate the chronic inflammatory state already caused by
gallstones (Wistuba and Gazdar, 2004; Jergens et al, 2007). In animal
studies, the sequence of events going from chronic inflammation to
cancer has been directly linked to some Helicobacter species. For
instance, H. hepaticus can cause chronic active infection of bile
canaliculi that progresses to liver carcinoma in A/JCr laboratory
strains of mice (Ward et al, 1994). Similarly, colon cancer in SMAD-
3-deficient mice is enhanced by dual infection with H. hepaticus and
H. bilis (Maggio-Price et al, 2006).
In conclusion, further development of PCR testing protocols is
required, as well as a better characterisation of antigens suitable
for histoimmunochemistry. As the BT is only accessible through
invasive procedure or surgery, the choice of controls who can
provide adequate specimens for case–control studies is limited.
Larger epidemiological studies will only be possible by developing
serological methods validated against direct detection of Helico-
bacter species in the gallbladder.
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